December 2014

A biomarker has been found that may help determine which Gleason 7 (GS7) cancers are particularly aggressive.

It's not uncommon for a business to use a superlative in its name, but Premier Medical Group in Poughkeepsie, NY, truly lives up to its moniker.

One-third of men over 70 years of age who undergo radical prostatectomy for prostate cancer and then experience biochemical recurrence have no need for salvage treatment, according to a recent study.

Urologists who are members of LUGPA are doing the right thing by being part of large group practices.

Drugs that inhibit the DNA repair enzyme poly(ADP-ribose) polymerase (PARP) have been shown to be effective in treating ovarian, breast, and prostate cancers in patients with inherited BRCA mutations. In broadening the therapeutic scope of PARP inhibitors beyond germline BRCA-mutated cancers.

Fats in blood and on the body increase men's prostate cancer risk, two studies have found.

The use of multiparametric MRI in diagnosing and treating prostate cancer was explored in November during a continuing medical education course offered at the annual meeting of LUGPA

While Laszewski said the Affordable Care Act (ACA), which is driving many of the changes, may end up being altered, he doesn't expect the program to be disbanded due to the political shift in legislative power.

In a constantly changing and thus difficult-to-navigate healthcare world, thriving in community practice is nothing if not challenging.

In attending the Society of Urologic Oncology's annual meeting in Bethesda in early December, I was struck by the number of presentations focusing sharply on the burgeoning fields of biomolecular markers and immunotherapy and their application to urologic oncology.